Arthrofoon - instructions for use, dose, side effects, contraindications

Similar drugsTo uncover

Dosage form: & nbsplozenges.

Composition:

Active components:

Antibodies to the human tumor necrosis factor alpha are affinity purified - 0.003 g *

Excipients: lactose monohydrate (lactose) 0.267 g, microcrystalline cellulose 0.03 g, magnesium stearate 0.003 g

* are applied to lactose in the form of a water-alcohol mixture with a content of not more than 10^-15 ng / g of the active form of the active ingredient.

Description:Tablets are flat-cylindrical, with a risk and chamfer, from white to almost white. On the flat side, MATERIA MEDICA is inscribed on the flat side, and the inscription ARTHROFON is on the other flat side.

Pharmacotherapeutic group:Anti-inflammatory. Immunomodulating agent

ATX: & nbsp

Other drugs for the treatment of diseases of the musculoskeletal system

Pharmacodynamics:It is experimentally and clinically proven that the drug modulates the production and functional activity of endogenous tumor necrosis factor alpha (TNFα) in rheumatoid arthritis, osteoarthritis, osteochondrosis, back pain; ulcerative colitis (NUC). Has anti-inflammatory and analgesic effect. By reducing the production of a number of pro-inflammatory cytokines, inflammatory mediators prevent the progression of inflammatory lesions of tissues and target organs in inflammatory-degenerative diseases of joints and NNC.

Pharmacokinetics:The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, chromatography-mass spectrometry) does not allow to estimate the content of ultra-small doses of antibodies in biological fluids, organs and tissues, which makes it technically impossible to study the pharmacokinetics of the drug Arthrofoon.

Indications:

Rheumatoid arthritis, osteoarthrosis (including spondylarthrosis) and other joint diseases. During remission, it is possible to use the drug as part of monotherapy, during an exacerbation - as part of a complex therapy (with non-steroidal anti-inflammatory drugs).

Nonspecific ulcerative colitis of mild and moderate severity.

Contraindications:

Increased individual sensitivity to the components of the drug.

It is not recommended for use in children and adolescents under the age of 18 (due to lack of clinical experience).

Pregnancy and lactation:The safety of the use of Arthrofoon in pregnant women and during lactation has not been studied. If necessary, taking the drug should take into account the risk / benefit ratio.

Dosing and Administration:

Inside.At one time - 2 tablets (keep in your mouth until completely dissolved - not during meals).

Rheumatoid arthritis, osteoarthrosis (including spondylarthrosis) and other joint diseases.

The drug should be taken twice a day, in the evening and in the morning (before and after sleep). The recommended duration of the drug is up to 6 months.

With severe pain in the first 2-4 weeks of therapy, the drug is recommended to be taken up to 4 times a day, as part of complex therapy. When the condition improves, gradually switch to taking 2 tablets 2 times a day.

Nonspecific ulcerative colitis.

The drug should be taken twice a day, in the evening and in the morning (before and after sleep). The recommended duration of the drug is up to 6 months.

With a marked exacerbation of the disease (abdominal pain, diarrhea) in the first 2-4 weeks of therapy, the drug is recommended to be taken up to 4 times a day. When the condition improves, gradually switch to taking 2 tablets 2 times a day.

Side effects:Possible reactions of increased individual sensitivity to the components of the drug.

Overdose:In case of an accidental overdose, dyspepsia is possible due to the excipients included in the formulation.

Interaction:Cases of incompatibility with other drugs have not been registered to date. Possible combination of the drug with non-steroidal anti-inflammatory drugs.

Special instructions:

On 3-5 days after the beginning of treatment, there may be a moderately pronounced transient increase in the pain syndrome or local manifestations of inflammation that does not require changes in the pharmacotherapy regimen. In some cases, with a marked increase in pain syndrome or local signs of inflammation, it is necessary to temporarily reduce the dose to 1-2 tablets per day.

The composition of the drug includes lactose monohydrate, and therefore it is not recommended for patients with congenital galactosemia, glucose malabsorption syndrome or galactose, or with congenital lactase insufficiency.

Effect on the ability to drive transp. cf. and fur:Arthrofoon does not affect the ability to drive vehicles and other potentially dangerous mechanisms.

Form release / dosage:Lozenges.

Packaging:

For 20 tablets in a planar cell packaging made of polyvinylchloride film and aluminum foil.

For 1, 2 or 5 contour mesh packages together with the instruction for medical use are placed in a pack of cardboard.

Storage conditions:

At a temperature of no higher than 25 ° C.

Keep out of the reach of children.

During the period of application of the preparation, store the contour mesh packaging in a cardboard bundle provided by the manufacturer.

Shelf life:

3 years.

Do not use after the expiration date.

Terms of leave from pharmacies:Without recipe

Registration number:P N000373 / 01

Date of registration:07.06.2010 / 18.08.2015

Expiration Date:Unlimited

The owner of the registration certificate:NPF Materia Medica Holding, OOO NPF Materia Medica Holding, OOO Russia

Manufacturer: & nbsp

NPF Materia Medica Holding, OOO Russia

Information update date: & nbsp14.09.2017

Illustrated instructions

Instructions

Arthrofoon (Arthrofon)